Promising advances emerged in targeted therapies against various cancers and neurological diseases. Vepdegestrant, a PROTAC-based SERD, outperformed fulvestrant in mutant ER+ breast cancer models, highlighting a potential new treatment avenue. Concurrently, combined use of two cancer drugs exhibited modification of Alzheimer’s pathology in murine models, suggesting a novel combination approach. Furthermore, research into glymphatic system asymmetry offers new insights into Parkinson’s disease lateralization. These developments advance understanding and treatment prospects across critical therapeutic areas.